Investigational hormone receptor agonists as ongoing female contraception: a focus on selective progesterone receptor modulators in early clinical development

Bibliography

• Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann 2014;45(3):301-14
   PubMed Web of Science ®Google Scholar
• Finer LB, Zolna MR. Shifts in intended and unintended pregnancies in the United States, 2001-2008. Am J Public Health 2014;104(Suppl 1):S43-8
   PubMed Web of Science ®Google Scholar
• Trussell J, Guthrie KA. Choosing a contraceptive: efficacy, safety, and personal considerations. Contraceptive Technology. 20th edition. Ardent Media; New York: NY: 2011. p. 50
   Google Scholar
• Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998;179(3 Pt 1):577-82
   PubMed Web of Science ®Google Scholar
• Westhoff CL, Heartwell S, Edwards S, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol 2007;196(4):412.e1-6
   Web of Science ®Google Scholar
• Pelican KM, Wildt DE, Howard JG. GnRH agonist Lupron (leuprolide acetate) pre-treatments prevent ovulation in response to gonadotropin stimulation in the clouded leopard (Neofelis nebulosa). Theriogenology 2006;66(6-7):1768-77
   PubMed Web of Science ®Google Scholar
• Siebert U, Driver J, Rosenberger T, Atkinson S. Reversible reproductive control in harbour seals (Phoca vitulina) with a gonadotropin-releasing hormone agonist. Theriogenology 2007;67(3):605-8
   PubMed Web of Science ®Google Scholar
• Metrione LC, Verstegen JP, Heard DJ, et al. Preliminary evaluation of deslorelin, a GnRH agonist for contraception of the captive variable flying fox Pteropus hypomelanus. Contraception 2008;78(4):336-45
   PubMed Web of Science ®Google Scholar
• Melville DF, O’Brien GM, Crichton EG, et al. Reproductive seasonality and the effect of the GnRH agonist deslorelin as a contraceptive in captive male Black Flying-foxes (Pteropus alecto). Theriogenology 2012;77(3):652-61
   PubMed Web of Science ®Google Scholar
• MacGregor MJ, Perkins EG, Asa C, Skinner DC. Contraception has gone to the coyotes (Canis latrans). J Zoo Wildl Med 2013;44(Suppl 4):S4-8
   Google Scholar
• Carranza A, Faya M, Merlo ML, et al. Effect of GnRH analogs in postnatal domestic cats. Theriogenology 2014;82(1):138-43
   PubMed Web of Science ®Google Scholar
• Rubion S, Driancourt MA. Controlled delivery of a GnRH agonist by a silastic implant (Gonazon) results in long-term contraception in queens. Reprod Domest Anim 2009;44(Suppl 2):79-82
   PubMed Web of Science ®Google Scholar
• Goericke-Pesch S, Georgiev P, Atanasov A, et al. Treatment of queens in estrus and after estrus with a GnRH-agonist implant containing 4.7 mg deslorelin; hormonal response, duration of efficacy, and reversibility. Theriogenology 2013;79(4):640-6
   PubMed Web of Science ®Google Scholar
• Maenhoudt C, Santos NR, Fontaine E, et al. Results of GnRH agonist implants in oestrous induction and oestrous suppression in bitches and queens. Reprod Domest Anim 2012;47(Suppl 6):393-7
   PubMed Web of Science ®Google Scholar
• Marino G, Rizzo S, Quartuccio M, et al. Deslorelin implants in pre-pubertal female dogs: short- and long-term effects on the genital tract. Reprod Domest Anim 2014;49(2):297-301
   PubMed Web of Science ®Google Scholar
• Lucas X. Clinical use of deslorelin (GnRH agonist) in companion animals: a review. Reprod Domest Anim 2014;49(Suppl 4):64-71
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Meduri G, Bouchard P, Spitz IM. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 2005;11(3):293-307
   PubMed Web of Science ®Google Scholar
• Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertil Steril 2011;96(5):1175-89
   PubMed Web of Science ®Google Scholar
• Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing’s syndrome. Eur J Endocrinol 2007;157(5):561-9
   PubMed Web of Science ®Google Scholar
• Morgan FH, Laufgraben MJ. Mifepristone for management of Cushing’s syndrome. Pharmacotherapy 2013;33(3):319-29
   PubMed Web of Science ®Google Scholar
• Castinetti F, Brue T, Conte-Devolx B. The use of the glucocorticoid receptor antagonist mifepristone in Cushing’s syndrome. Curr Opin Endocrinol DiabetesObes 2012;19(4):295-9
   Google Scholar
• Mahajan DK, London SN. Mifepristone (RU486): a review. Fertil Steril 1997;68(6):967-76
   PubMed Web of Science ®Google Scholar
• Dzuba IG, Grossman D, Schreiber CA. Off-label indications for mifepristone in gynecology and obstetrics. Contraception 2015. [Epub ahead of print]
   PubMedGoogle Scholar
• Spitz IM. Mifepristone: where do we come from and where are we going? Clinical development over a quarter of a century. Contraception 2010;82(5):442-52
   PubMed Web of Science ®Google Scholar
• Carbonell JL, Garcia R, Gonzalez A, et al. Mifepristone 5 mg versus 10 mg for emergency contraception: double-blind randomized clinical trial. Int J Womens Health 2015;7:95-102
   PubMedGoogle Scholar
• Brache V, Cochon L, Deniaud M, Croxatto HB. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception 2013;88(5):611-18
   PubMed Web of Science ®Google Scholar
• Glasier A, Cameron ST, Blithe D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011;84(4):363-7
   PubMed Web of Science ®Google Scholar
• Russo JA, Creinin MD. Ulipristal acetate for emergency contraception. Drugs Today (Barc) 2010;46(9):655-60
   PubMed Web of Science ®Google Scholar
• Gizzo S, Fanelli T, Di Gangi S, et al. Nowadays which emergency contraception? Comparison between past and present: latest news in terms of clinical efficacy, side effects and contraindications. Gynecol Endocrinol 2012;28(10):758-63
   PubMed Web of Science ®Google Scholar
• Grow DR, Williams RF, Hsiu JG, Hodgen GD. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J Clin Endocrinol Metab 1996;81(5):1933-9
   PubMed Web of Science ®Google Scholar
• Kettel LM, Murphy AA, Morales AJ, Yen SS. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am J Obstet Gynecol 1998;178(6):1151-6
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Brenner RM, Fuhrmann UU, et al. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000;65(10-11):741-51
   PubMed Web of Science ®Google Scholar
• Brenner RM, Slayden OD, Nath A, et al. Intrauterine administration of CDB-2914 (Ulipristal) suppresses the endometrium of rhesus macaques. Contraception 2010;81(4):336-42
   PubMed Web of Science ®Google Scholar
• Ioffe OB, Zaino RJ, Mutter GL. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod Pathol 2009;22(3):450-9
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, Hamberg M. The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2 alpha concentrations. Hum Reprod 1994;9(9):1626-30
   PubMed Web of Science ®Google Scholar
• Gemzell-Danielsson K, van Heusden AM, Killick SR, et al. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new anti-progestogen. Hum Reprod 2002;17(10):2588-93
   PubMed Web of Science ®Google Scholar
• Massai MR, Pavez M, Fuentealba B, et al. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception 2004;70(1):47-54
   PubMed Web of Science ®Google Scholar
• Morison NB, Kaitu’u-Lino TJ, Fraser IS, Salamonsen LA. Stimulation of epithelial repair is a likely mechanism for the action of mifepristone inreducing duration of bleeding in users of progestogen-only contraceptives. Reproduction 2008;136(2):267-74
   PubMed Web of Science ®Google Scholar
• Chen W, Ohara N, Wang J, et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006;91(4):1296-304
   PubMed Web of Science ®Google Scholar
• Luo X, Yin P, Coon V JS, et al. The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells. Fertil Steril 2010;93(8):2668-73
   PubMed Web of Science ®Google Scholar
• Maruo T, Ohara N, Yoshida S, et al. Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system. Contraception 2010;82(5):435-41
   PubMed Web of Science ®Google Scholar
• Xu Q, Takekida S, Ohara N, et al. Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5’-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells. J Clin Endocrinol Metab 2005;90(2):953-61
   PubMed Web of Science ®Google Scholar
• Philibert D. RU 38486: an original multifaceted antihormone in vivo. In: Agarwal M, editors. Adrenal steroid antagonism. Walter de Gruyter; Berlin: 1984. p. 77-101
   Google Scholar
• Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2012;97(6):2039-49
   PubMed Web of Science ®Google Scholar
• Gainer EE, Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids 2003;68(10-13):1005-11
   PubMed Web of Science ®Google Scholar
• Nallasamy S, Kim J, Sitruk-Ware R, et al. Ulipristal blocks ovulation by inhibiting progesterone receptor-dependent pathways intrinsic to the ovary. Reprod Sci 2013;20(4):371-81
   PubMed Web of Science ®Google Scholar
• Hild SA, Reel JR, Hoffman LH, Blye RP. CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits. Hum Reprod 2000;15(4):822-9
   PubMed Web of Science ®Google Scholar
• Reel JR, Hild-Petito S, Blye RP. Antiovulatory and postcoital antifertility activity of the antiprogestin CDB-2914 when administered as single, multiple, or continuous doses to rats. Contraception 1998;58(2):129-36
   PubMed Web of Science ®Google Scholar
• Brache V, Sitruk-Ware R, Williams A, et al. Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women. Contraception 2012;85(5):480-8
   PubMed Web of Science ®Google Scholar
• Mozzanega B 678
   Google Scholar
• Cameron ST, Critchley HO, Thong KJ, et al. Effects of daily low dose mifepristone on endometrial maturation and proliferation. Hum Reprod 1996;11(11):2518-26
   PubMed Web of Science ®Google Scholar
• Gravanis A, Schaison G, George M, et al. Endometrial and pituitary responses to the steroidal antiprogestin RU 486 in postmenopausal women. J Clin Endocrinol Metab 1985;60(1):156-63
   PubMed Web of Science ®Google Scholar
• Li HW, Liao SB, Yeung WS, et al. Ulipristal acetate resembles mifepristone in modulating human fallopian tube function. Hum Reprod 2014;29(10):2156-62
   PubMed Web of Science ®Google Scholar
• Wånggren K, Stavreus-Evers A, Olsson C, et al. Regulation of muscular contractions in the human Fallopian tube through prostaglandins and progestagens. Hum Reprod 2008;23(10):2359-68
   PubMed Web of Science ®Google Scholar
• Ko JK, Huang VW, Li RH, et al. An in vitro study of the effect of mifepristone and ulipristal acetate on human sperm functions. Andrology 2014;2(6):868-74
   Web of Science ®Google Scholar
• Blithe DL, Nieman LK, Blye RP, et al. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids 2003;68(10-13):1013-17
   PubMed Web of Science ®Google Scholar
• Sarkar NN. Barriers to emergency contraception (EC): does promoting EC increase risk for contacting sexually transmitted infections, HIV/AIDS? Int J Clin Pract 2008;62(11):1769-75
   PubMed Web of Science ®Google Scholar
• Larner JM, Reel JR, Blye RP. Circulating concentrations of the antiprogestins CDB-2914 and mifepristone in the female rhesus monkey following various routes of administration. Hum Reprod 2000;15(5):1100-6
   PubMed Web of Science ®Google Scholar
• Glasier A, Thong KJ, Dewar M, et al. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992;327(15):1041-4
   PubMed Web of Science ®Google Scholar
• Glasier A. Emergency postcoital contraception. N Engl J Med 1979;337(15):1058-64
   Google Scholar
• Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87(1):63-70
   PubMed Web of Science ®Google Scholar
• Lakha F, Ho PC, Van der Spuy ZM, et al. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007;22(9):2428-36
   PubMed Web of Science ®Google Scholar
• Chen X, Xiao B. Effect of once weekly administration of mifepristone on ovarian function in normal women. Contraception 1997;56(3):175-80
   PubMed Web of Science ®Google Scholar
• Godfrey EM, Mawson JT, Stanwood NL, et al. Low-dose mifepristone for contraception: a weekly versus planned postcoital randomized pilot study. Contraception 2004;70(1):41-6
   PubMed Web of Science ®Google Scholar
• Marions L, Danielsson KG, Swahn ML, Bygdeman M. Contraceptive efficacy of low doses of mifepristone. Fertil Steril 1998;70(5):813-16
   PubMed Web of Science ®Google Scholar
• Spitz IM, Croxatto HB, Salvatierra AM, Heikinheimo O. Response to intermittent RU486 in women. Fertil Steril 1993;59(5):971-5
   PubMed Web of Science ®Google Scholar
• Pei K, Xiao B, Jing X, et al. Weekly contraception with mifepristone. Contraception 2007;75(1):40-4
   PubMed Web of Science ®Google Scholar
• Agarwal M, Das V, Agarwal A, et al. Evaluation of mifepristone as a once a month contraceptive pill. Am J Obstet Gynecol 2009;200(5):e27-9
   Google Scholar
• Sitruk-Ware R. Mifepristone and misoprostol sequential regimen side effects, complications and safety. Contraception 2006;74(1):48-55
   PubMed Web of Science ®Google Scholar
• Jensen JT. Vaginal ring delivery of selective progesterone receptor modulators for contraception. Contraception 2013;87(3):314-18
   PubMed Web of Science ®Google Scholar
• Huang Y, Jensen JT, Brache V, et al. A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: research for a novel estrogen-free, method of contraception. Contraception 2014;90(6):565-74
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P; VA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2007;92(9):3582-9
   PubMed Web of Science ®Google Scholar
• Lakha F, Ho PC, Van der Spuy ZM, et al. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod 2007;22(9):2428-36
   PubMed Web of Science ®Google Scholar
• Dinh A, Sriprasert I, Williams AR, Archer DF. A review of the endometrial histologic effects of progestins and progesterone receptor modulators in reproductive age women. Contraception 2015;91(5):360-7
   PubMed Web of Science ®Google Scholar
• Donnez J, Hudecek R, Donnez O, et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015;103(2):519-27.e3
   PubMed Web of Science ®Google Scholar
• Williams AR, Bergeron C, Barlow DH, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012;31(6):556-69
   PubMed Web of Science ®Google Scholar
• Luyckx M, Squifflet JL, Jadoul P, et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014;102(5):1404-9
   PubMed Web of Science ®Google Scholar
• DeManno D, Elger W, Garg R, et al. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68(10-13):1019-32
   PubMed Web of Science ®Google Scholar
• Chwalisz K, Elger W, Stickler T, et al. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005;20(4):1090-9
   PubMed Web of Science ®Google Scholar
• Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod 2006;21(1):295-302
   PubMed Web of Science ®Google Scholar
• Jain JK, Li A, Yang W, et al. Mifepristone alters expression of endometrial steroid receptors and their cofactors in new users of medroxyprogesterone acetate. Fertil Steril 2007;87(1):8-23
   PubMed Web of Science ®Google Scholar
• World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 2015. Available from: http://apps.who.int/iris/bitstream/10665/173585/1/9789241549257_eng.pdf?ua=1
   Google Scholar
• United States Medical Eligibility Criteria (US MEC) for Contraceptive Use. 2010. Available from: http://www.cdc.gov/reproductivehealth/unintendedpregnancy/usmec.htm
   Google Scholar
• Birgisson NE, Zhao Q, Secura GM, et al. Preventing Unintended Pregnancy: The Contraceptive CHOICE Project in Review. J Womens Health (Larchmt) 2015;24(5):349-53
   PubMed Web of Science ®Google Scholar